Intellia Therapeutics (NTLA)
(Delayed Data from NSDQ)
$21.46 USD
-0.92 (-4.11%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $21.44 -0.02 (-0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Intellia Therapeutics, Inc. [NTLA]
Reports for Purchase
Showing records 181 - 200 ( 290 total )
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia Gives Birth to an Adolescent CAR-T Company With Superior Genetics; Reiterate Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage of Intellia; Poised For Success With One and Done- CRISPR/Cas9 Cures for Genetic Diseases
Provider: H.C. Wainwright & Co., Inc.
Analyst: KING M
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Intellia at the American Society of Gene and Cell Therapy Meeting
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21 Financials; AT The Ready for ATTR Data Mid-year
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: Data Readout for ATTR Slated for Mid-2021. Rating Buy. PT to $80.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Intellia Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q20 - Timing of the ATTR Trial Initial Readout is Crucial
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T